Stockreport

Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma (HNSCC)

Agilent Technologies, Inc.  (A) 
Last agilent technologies, inc. earnings: 2/18 04:05 pm Check Earnings Report
US:NYSE Investor Relations: investor.agilent.com
PDF PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify HNSCC patients for treatment with KEYTRUDA® (pembrolizumab) SANTA CLARA, Calif.--(BUSI [Read more]